All news

Barclays trims Welltower price target to $246

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

Barclays analyst Richard Hightower kept an Equal-Weight rating on Welltower (WELL) while cutting the price target to $246.00 from $259.00. The healthcare REIT trades at $230.29, a 12.8% premium to its GF Value of $204.32, suggesting overvaluation. Its GF Score of 86/100 and notable insider buying signal underlying confidence. The lower target trims expected upside for investors holding the stock.

Read original source

WELL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.